Class information for:
Level 1: VEMURAFENIB//B RAF//BRAF INHIBITOR

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
2066 2301 46.3 90%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
206 20344 MELANOMA//MALIGNANT MELANOMA//DERMOSCOPY

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 VEMURAFENIB Author keyword 143 61% 7% 150
2 B RAF Author keyword 101 25% 15% 346
3 BRAF INHIBITOR Author keyword 100 79% 3% 64
4 DABRAFENIB Author keyword 93 79% 3% 60
5 TRAMETINIB Author keyword 75 83% 2% 43
6 NRAS Author keyword 51 48% 3% 77
7 BRAF INHIBITORS Author keyword 42 74% 1% 31
8 B RAF INHIBITOR Author keyword 37 100% 1% 14
9 MEK INHIBITOR Author keyword 33 44% 2% 57
10 SIGNAL TRANSDUCT TEAM Address 27 60% 1% 29

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 VEMURAFENIB 143 61% 7% 150 Search VEMURAFENIB Search VEMURAFENIB
2 B RAF 101 25% 15% 346 Search B+RAF Search B+RAF
3 BRAF INHIBITOR 100 79% 3% 64 Search BRAF+INHIBITOR Search BRAF+INHIBITOR
4 DABRAFENIB 93 79% 3% 60 Search DABRAFENIB Search DABRAFENIB
5 TRAMETINIB 75 83% 2% 43 Search TRAMETINIB Search TRAMETINIB
6 NRAS 51 48% 3% 77 Search NRAS Search NRAS
7 BRAF INHIBITORS 42 74% 1% 31 Search BRAF+INHIBITORS Search BRAF+INHIBITORS
8 B RAF INHIBITOR 37 100% 1% 14 Search B+RAF+INHIBITOR Search B+RAF+INHIBITOR
9 MEK INHIBITOR 33 44% 2% 57 Search MEK+INHIBITOR Search MEK+INHIBITOR
10 PLX4032 25 73% 1% 19 Search PLX4032 Search PLX4032

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 B RAF 190 28% 26% 590
2 VEMURAFENIB 154 52% 9% 209
3 MEK INHIBITION 137 57% 7% 161
4 RAF INHIBITORS 129 76% 4% 91
5 AZD6244 ARRY 142886 81 65% 3% 77
6 METASTATIC MELANOMA 77 11% 28% 653
7 DABRAFENIB 76 70% 3% 64
8 PLX4032 73 89% 1% 33
9 RAF INHIBITION 71 75% 2% 51
10 RAF INHIBITOR RESISTANCE 64 75% 2% 47

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PIGMENT CELL & MELANOMA RESEARCH 13 15% 3% 79

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Beyond BRAF: where next for melanoma therapy? 2015 6 84 80%
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies 2015 3 94 78%
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond 2014 32 138 55%
Resistance to BRAF-targeted therapy in melanoma 2013 64 57 72%
Which drug, and when, for patients with BRAF-mutant melanoma? 2013 67 53 62%
Resistance to RAF Inhibitors Revisited 2014 14 49 92%
Tumor adaptation and resistance to RAF inhibitors 2013 85 103 47%
Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma 2015 2 60 72%
Targeted therapy for melanoma: rational combinatorial approaches 2014 15 70 70%
MEK in cancer and cancer therapy 2014 22 122 52%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SIGNAL TRANSDUCT TEAM 27 60% 1.3% 29
2 MELANOMA MED ONCOL 16 21% 2.9% 66
3 GENE ONCOGENE TARGETING TEAM 15 82% 0.4% 9
4 MELANOMA AUSTRALIA 8 28% 1.0% 24
5 CUTANEOUS ONCOL 7 18% 1.4% 33
6 SURG ONCOL MED ONCOL DERMATOL 6 100% 0.2% 4
7 MELANOMA 5 16% 1.2% 27
8 FOREMAN FDN MELANOMA 4 39% 0.4% 9
9 MELANOMA THER EUT PROGRAM 4 67% 0.2% 4
10 WESTMEAD CANC 4 11% 1.7% 39

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000081011 BIOCHEMOTHERAPY//METASTATIC MELANOMA//DACARBAZINE
2 0.0000079096 DICER//DROSHA//MICROPROCESSOR COMPLEX
3 0.0000077084 CDKN2A//MC1R//MELANOCORTIN 1 RECEPTOR
4 0.0000075220 DIARYLAMIDE//VEGFR 2 INHIBITOR//KDR KINASE
5 0.0000074311 KSR1//PEA 15//IST ENDOCRINOL ONCOL SPERIMENTALE GAETANO SALVA
6 0.0000073149 RAF//RAF 1//LEO JENKINS CANC
7 0.0000061215 CTLA 4//IPILIMUMAB//CYTOTOXIC T LYMPHOCYTE ANTIGEN 4
8 0.0000051993 DYSPLASTIC NEVUS//DYSPLASTIC NEVUS SYNDROME//DYSPLASTIC NEVI
9 0.0000051855 RET PTC//PAPILLARY THYROID CARCINOMA//HBME 1
10 0.0000051542 EVOLUT CANC//PETOS PARADOX//TRANSLAT CANC THER EUT